OPB-111001
- Generic Name
- OPB-111001
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Phase 1
Terminated
- Conditions
- Breast CancerOvarian CancerProstate CancerSalivary Gland CancerEndometrial CancerSquamous Cell Carcinoma of the Cervix
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Otsuka Novel Products GmbH
- Target Recruit Count
- 79
- Registration Number
- NCT02042885
- Locations
- 🇬🇧
NIHR/Wellcome Trust Imperial CRF/Imperial College Healthcare NHS Trust, Imperial Centre for Translational and Experimental Medicine (L-Block), Hammersmith Hospital, London, United Kingdom
🇬🇧The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, Sutton, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath